Please use a PC Browser to access Register-Tadawul
How Bristow’s $400 Million 2033 Secured Notes Refinancing Will Impact Bristow Group (VTOL) Investors
Bristow Group Inc VTOL | 46.61 | -0.64% |
- Bristow Group Inc. recently completed a private offering of US$400 million in senior secured notes due 2033, guaranteed by key subsidiaries and secured against helicopters and other operating assets, to fund the full redemption of its existing 6.875% senior secured notes due 2028.
- This refinancing reshapes Bristow’s debt profile by extending maturities and pledging approximately 70 aircraft as collateral, an important shift for a capital-intensive aviation services business.
- Next, we’ll explore how replacing the 2028 notes with new 2033 senior secured debt could influence Bristow’s investment narrative and risk profile.
These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
Bristow Group Investment Narrative Recap
To own Bristow Group, you need to believe in resilient demand for offshore transport and government search and rescue services, backed by disciplined capital and fleet management. The new US$400 million secured notes, used to retire the 2028 debt, mainly tidy up the balance sheet timing and collateral rather than changing the near term earnings catalyst or the biggest risk around ongoing capital intensity and cost inflation.
The recent decision to introduce a quarterly dividend from Q1 2026 and maintain an active US$125 million buyback program sits alongside this refinancing, giving a clearer picture of how Bristow is balancing shareholder returns with its heavy funding needs for helicopters and government contracts. Taken together, these moves frame the trade off between rewarding shareholders today and preserving flexibility for future fleet upgrades and emerging technologies.
Yet investors should also be aware that Bristow’s sizeable, asset backed debt load means that if conditions turn and fleet values weaken...
Bristow Group's narrative projects $1.9 billion revenue and $129.4 million earnings by 2028. This requires 9.0% yearly revenue growth and about a $10.3 million earnings increase from $119.1 million today.
Uncover how Bristow Group's forecasts yield a $47.50 fair value, a 19% upside to its current price.
Exploring Other Perspectives
Two Simply Wall St Community fair value estimates span from about US$6.80 to US$47.50, highlighting very different views on Bristow’s worth. When you set this against the company’s substantial asset backed debt and capital needs, it underlines why many investors look at several risk and return scenarios before forming an opinion.
Explore 2 other fair value estimates on Bristow Group - why the stock might be worth less than half the current price!
Build Your Own Bristow Group Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Bristow Group research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Bristow Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristow Group's overall financial health at a glance.
Ready For A Different Approach?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.


